Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Abpro CorpABP · Entity 166815 | Chief Scientific Officer | May 10, 2018 | May 10, 2018 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Director · Chief Executive Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Abpro Corp
Report date May 10, 2018 · Filed May 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2027-07-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-05-10 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: (i) 2,172 of the shares underlying this option vested immediately on the grant date, (ii) 32,585 shares will vest upon certain performance criteria, as amended in April 2018, namely, upon Issuer filing an investigational drug application on any program, provided such application is filed on or before June 30, 2019, (iii) and 170,212 shares underlying this option shall vest and become exercisable as to 25% on the one-year anniversary of the grant date and the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: (i) 2,172 of the shares underlying this option vested immediately on the grant date, (ii) 32,585 shares will vest upon certain performance criteria, as amended in April 2018, namely, upon Issuer filing an investigational drug application on any program, provided such application is filed on or before June 30, 2019, (iii) and 170,212 shares underlying this option shall vest and become exercisable as to 25% on the one-year anniversary of the grant date and the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date.
TScan Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 1,049,767 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,000,000 · Balance 1,049,767 F1: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantVoting Common Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-412521 · ownership.xml · nonDerivative · entry 1 MacBeath Gavin · CIK 0001738082 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,049,767 F1 · kind: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:48 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 1,165,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001193125-26-019723 · ownership.xml · derivative · entry 1 MacBeath Gavin · CIK 0001738082 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,165,000 Underlying: Voting Common Stock · 1,165,000 shares Expires 2036-01-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 03, 2025 Filed Feb 11, 2025 22:52 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000950170-25-018125 · ownership.xml · derivative · entry 2 MacBeath Gavin · CIK 0001738082 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Voting Common Stock · 800,000 shares Expires 2035-01-03 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| January 12, 2024 Filed Feb 11, 2025 22:52 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000950170-25-018125 · ownership.xml · derivative · entry 1 MacBeath Gavin · CIK 0001738082 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Voting Common Stock · 160,000 shares Expires 2034-01-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:08 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 1,121,300 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0000899243-23-015635 · doc4.xml · derivative · entry 1 MacBeath Gavin · CIK 0001738082 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,121,300 Underlying: Voting Common Stock · 1,121,300 shares Expires 2033-06-12 F1 · derivative.exercise_date: 536,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 585,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 22:16 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-23-004062 · doc4.xml · derivative · entry 1 MacBeath Gavin · CIK 0001738082 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Voting Common Stock · 40,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 20:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-22-026844 · doc4.xml · derivative · entry 1 MacBeath Gavin · CIK 0001738082 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Voting Common Stock · 100,000 shares Expires 2032-07-24 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:26 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0000899243-22-002651 · doc4.xml · derivative · entry 1 MacBeath Gavin · CIK 0001738082 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Voting Common Stock · 140,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 22:48 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | PurchaseVoting Common Stock | 57 | $6.19 | $352.72 |
DisclosureSEC source: 0000899243-21-037147 · doc4.xml · nonDerivative · entry 2 MacBeath Gavin · CIK 0001738082 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,767 Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 22:48 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | PurchaseVoting Common Stock | 4,943 | $6.22 | $30,743.98 |
DisclosureSEC source: 0000899243-21-037147 · doc4.xml · nonDerivative · entry 1 MacBeath Gavin · CIK 0001738082 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,710 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $6.09 to $6.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.